23.53 USD
-2.49 (-9.57%)
23.53 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to PCRX. PCRX was compared to 191 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX has a bad growth rate and is valued cheaply. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
In the past year PCRX was profitable.
PCRX had a positive operating cash flow in the past year.
PCRX had positive earnings in 4 of the past 5 years.
In the past 5 years PCRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.65%, PCRX belongs to the top of the industry, outperforming 81.15% of the companies in the same industry.
With an excellent Return On Equity value of 2.95%, PCRX belongs to the best of the industry, outperforming 82.20% of the companies in the same industry.
PCRX has a Return On Invested Capital of 3.63%. This is amongst the best in the industry. PCRX outperforms 81.68% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
PCRX's Profit Margin of 2.99% is fine compared to the rest of the industry. PCRX outperforms 79.58% of its industry peers.
The Operating Margin of PCRX (8.88%) is better than 81.15% of its industry peers.
In the last couple of years the Operating Margin of PCRX has grown nicely.
PCRX's Gross Margin of 79.17% is amongst the best of the industry. PCRX outperforms 84.29% of its industry peers.
In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PCRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for PCRX has been increased compared to 5 years ago.
PCRX has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 2.10 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
PCRX has a Altman-Z score (2.10) which is comparable to the rest of the industry.
PCRX has a debt to FCF ratio of 3.03. This is a good value and a sign of high solvency as PCRX would need 3.03 years to pay back of all of its debts.
The Debt to FCF ratio of PCRX (3.03) is better than 90.05% of its industry peers.
PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
PCRX has a Debt to Equity ratio of 0.52. This is in the lower half of the industry: PCRX underperforms 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 2.1 |
ROIC/WACC0.45
WACC8.04%
2.3 Liquidity
A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
PCRX has a Current ratio of 5.26. This is in the better half of the industry: PCRX outperforms 64.40% of its industry peers.
A Quick Ratio of 3.78 indicates that PCRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.78, PCRX is in line with its industry, outperforming 59.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
The earnings per share for PCRX have decreased by -6.90% in the last year.
Measured over the past years, PCRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.96% on average per year.
PCRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.85%.
Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 10.73% on average per year.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
Based on estimates for the next years, PCRX will show a small growth in Earnings Per Share. The EPS will grow by 7.17% on average per year.
PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.09% yearly.
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PCRX is valuated cheaply with a Price/Earnings ratio of 7.92.
Based on the Price/Earnings ratio, PCRX is valued cheaper than 92.15% of the companies in the same industry.
PCRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
Based on the Price/Forward Earnings ratio of 6.73, the valuation of PCRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, PCRX is valued cheaper than 92.15% of the companies in the same industry.
PCRX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 23.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.92 | ||
| Fwd PE | 6.73 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 91.62% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PCRX is valued cheaply inside the industry as 92.15% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.15 | ||
| EV/EBITDA | 7.45 |
4.3 Compensation for Growth
The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y4.39%
EPS Next 3Y6.17%
5. Dividend
5.1 Amount
PCRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.53
-2.49 (-9.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners114.44%
Inst Owner Change0%
Ins Owners0.79%
Ins Owner Change-1.27%
Market Cap1.01B
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (28.81%)
Short Float %17.4%
Short Ratio9.43
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)-19.69%
PT rev (3m)-20.55%
EPS NQ rev (1m)0.97%
EPS NQ rev (3m)6.1%
EPS NY rev (1m)0.17%
EPS NY rev (3m)4.05%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.92 | ||
| Fwd PE | 6.73 | ||
| P/S | 1.41 | ||
| P/FCF | 8.15 | ||
| P/OCF | 7.16 | ||
| P/B | 1.39 | ||
| P/tB | 3.12 | ||
| EV/EBITDA | 7.45 |
EPS(TTM)2.97
EY12.62%
EPS(NY)3.5
Fwd EY14.87%
FCF(TTM)2.89
FCFY12.27%
OCF(TTM)3.29
OCFY13.97%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.57
Graham Number33.61
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 2.1 |
F-Score7
WACC8.04%
ROIC/WACC0.45
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-5.84%
EPS Next 2Y4.39%
EPS Next 3Y6.17%
EPS Next 5Y7.17%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.36%
Revenue Next 2Y6.92%
Revenue Next 3Y7.35%
Revenue Next 5Y6.09%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.52%
EBIT Next 3Y6.95%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.92 and the Price/Book (PB) ratio is 1.39.